Mucopolysaccharidosis Type VI


Is there a treatment(s) for Mucopolysaccharidosis Type VI?

The United States Food and Drug Administration (FDA) approved the use of a medication called galsulfase (also known as Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI) in June of 2005. Galsulfase is an enzyme replacement therapy using a man-made version of arylsulfatase B, which is the enzyme that is not working properly in MPS VI. While galsulfase is not a cure for MPS VI, it helps reduce the amount of glycosaminoglycans building up in the body, which may help slow the disease process and improve symptoms.

Maroteaux-Lamy Syndrome Resource Center -

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Remember Me